163 related articles for article (PubMed ID: 30657338)
1. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.
Shafique M; Tanvetyanon T
Expert Opin Biol Ther; 2019 Mar; 19(3):225-232. PubMed ID: 30657338
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in non-small cell lung cancer: advancements and challenges.
Zhou F; Zhou CC
Chin Med J (Engl); 2021 Feb; 134(10):1135-1137. PubMed ID: 33595975
[No Abstract] [Full Text] [Related]
3. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer.
Wang Y; Pattarayan D; Huang H; Zhao Y; Li S; Wang Y; Zhang M; Li S; Yang D
Nat Commun; 2024 Apr; 15(1):3178. PubMed ID: 38609378
[TBL] [Abstract][Full Text] [Related]
4. Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer.
Wang Y; Pattarayan D; Huang H; Zhao Y; Li S; Wang Y; Zhang M; Li S; Yang D
Res Sq; 2023 Sep; ():. PubMed ID: 37790509
[TBL] [Abstract][Full Text] [Related]
5. Combination of chemotherapy and immunotherapy may overcome the resistance to immunotherapy alone in pulmonary lymphoepithelial carcinoma.
Hung HY; Lai WA; Chuang CH; Yang CJ
Kaohsiung J Med Sci; 2024 Jun; 40(6):601-602. PubMed ID: 38590264
[No Abstract] [Full Text] [Related]
6. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB
Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
Pujol JL; Greillier L; Audigier-Valette C; Moro-Sibilot D; Uwer L; Hureaux J; Guisier F; Carmier D; Madelaine J; Otto J; Gounant V; Merle P; Mourlanette P; Molinier O; Renault A; Rabeau A; Antoine M; Denis MG; Bommart S; Langlais A; Morin F; Souquet PJ
J Thorac Oncol; 2019 May; 14(5):903-913. PubMed ID: 30664989
[TBL] [Abstract][Full Text] [Related]
8. First-line checkpoint inhibitors for wild-type advanced non-small-cell cancer: a pair-wise and network meta-analysis.
Wang XJ; Lin JZ; Yu SH; Wu SX; Luo HS; Du ZS; Li XY
Immunotherapy; 2019 Mar; 11(4):311-320. PubMed ID: 30678553
[TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM; Pabla S; Nesline MK; Glenn ST; Papanicolau-Sengos A; Burgher B; Andreas J; Giamo V; Wang Y; Lenzo FL; Bshara W; Khalil M; Dy GK; Madden KG; Shirai K; Dragnev K; Tafe LJ; Zhu J; Labriola M; Marin D; McCall SJ; Clarke J; George DJ; Zhang T; Zibelman M; Ghatalia P; Araujo-Fernandez I; de la Cruz-Merino L; Singavi A; George B; MacKinnon AC; Thompson J; Singh R; Jacob R; Kasuganti D; Shah N; Day R; Galluzzi L; Gardner M; Morrison C
J Immunother Cancer; 2019 Jan; 7(1):18. PubMed ID: 30678715
[TBL] [Abstract][Full Text] [Related]
11. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab resolves adult ashy dermatosis developing in patients with squamous cell carcinoma of the lung.
Takeda K; Fujimura T; Tsuchiyama K; Lyu C; Aiba S
J Dermatol; 2019 Mar; 46(3):271-273. PubMed ID: 30663147
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
14. An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
Vuong L; Kouverianou E; Rooney CM; McHugh BJ; Howie SEM; Gregory CD; Forbes SJ; Henderson NC; Zetterberg FR; Nilsson UJ; Leffler H; Ford P; Pedersen A; Gravelle L; Tantawi S; Schambye H; Sethi T; MacKinnon AC
Cancer Res; 2019 Apr; 79(7):1480-1492. PubMed ID: 30674531
[TBL] [Abstract][Full Text] [Related]
15. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation.
Ueno R; Nemoto M; Uegami W; Fukuoka J; Misawa M
Respir Med Case Rep; 2019; 26():168-170. PubMed ID: 30671338
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors.
Youssef A; Kasso N; Torloni AS; Stanek M; Dragovich T; Gimbel M; Mahmoud F
Case Rep Hematol; 2018; 2018():2464619. PubMed ID: 30671268
[TBL] [Abstract][Full Text] [Related]
18. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review.
Belgioia L; Desideri I; Errico A; Franzese C; Daidone A; Marino L; Fiore M; Borghetti P; Greto D; Fiorentino A;
Crit Rev Oncol Hematol; 2019 Jan; 133():163-170. PubMed ID: 30661652
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J
J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
